Patients with the ALK+ NSCLC subtype have been found to have improved clinical outcomes when treated with ALK tyrosine kinase inhibitors (ALK‐TKIs), which has led to the approval of agents such as crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib [2]. This evidence concerns the gene ALK and non-small cell lung carcinoma.